NO319903B1 - Anvendelse av et antistoffmolekyl for fremstilling av et farmasoytisk preparat for behandling av plateepitelkarsinom. - Google Patents
Anvendelse av et antistoffmolekyl for fremstilling av et farmasoytisk preparat for behandling av plateepitelkarsinom. Download PDFInfo
- Publication number
- NO319903B1 NO319903B1 NO19982588A NO982588A NO319903B1 NO 319903 B1 NO319903 B1 NO 319903B1 NO 19982588 A NO19982588 A NO 19982588A NO 982588 A NO982588 A NO 982588A NO 319903 B1 NO319903 B1 NO 319903B1
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- biwa
- antibodies
- tumor
- expression
- Prior art date
Links
- 206010041823 squamous cell carcinoma Diseases 0.000 title claims description 31
- 238000011282 treatment Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 230000002285 radioactive effect Effects 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- 238000010188 recombinant method Methods 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 230000001588 bifunctional effect Effects 0.000 claims description 3
- 239000000824 cytostatic agent Substances 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 34
- 108010058905 CD44v6 antigen Proteins 0.000 description 27
- 210000004881 tumor cell Anatomy 0.000 description 24
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 238000010186 staining Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 102100032912 CD44 antigen Human genes 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 10
- 108010029485 Protein Isoforms Proteins 0.000 description 10
- 102000001708 Protein Isoforms Human genes 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 208000009956 adenocarcinoma Diseases 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000000867 larynx Anatomy 0.000 description 7
- 206010027457 Metastases to liver Diseases 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 101150017002 CD44 gene Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 201000001514 prostate carcinoma Diseases 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002991 immunohistochemical analysis Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 201000004916 vulva carcinoma Diseases 0.000 description 2
- 208000013013 vulvar carcinoma Diseases 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101100059521 Homo sapiens CD44 gene Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 238000011794 NU/NU nude mouse Methods 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010048757 Oncocytoma Diseases 0.000 description 1
- 208000002063 Oxyphilic Adenoma Diseases 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000036844 Squamous cell carcinoma of the larynx Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000004732 colorectal carcinogenesis Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000011347 external beam therapy Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 102000048851 human CD44 Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- -1 isothiocyanate-benzyl-diethylenetriamine pentaacetate Chemical compound 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007653 larval development Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19545472A DE19545472A1 (de) | 1995-12-06 | 1995-12-06 | Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen |
| DE19615074 | 1996-04-17 | ||
| PCT/EP1996/005448 WO1997021104A1 (de) | 1995-12-06 | 1996-12-05 | Verfahren zur diagnose und therapie von plattenepithelkarzinomen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO982588D0 NO982588D0 (no) | 1998-06-05 |
| NO982588L NO982588L (no) | 1998-08-05 |
| NO319903B1 true NO319903B1 (no) | 2005-09-26 |
Family
ID=26020988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19982588A NO319903B1 (no) | 1995-12-06 | 1998-06-05 | Anvendelse av et antistoffmolekyl for fremstilling av et farmasoytisk preparat for behandling av plateepitelkarsinom. |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0865609B1 (et) |
| JP (1) | JP2000502067A (et) |
| KR (1) | KR100473824B1 (et) |
| CN (1) | CN1151377C (et) |
| AR (1) | AR004360A1 (et) |
| AT (1) | ATE235056T1 (et) |
| AU (1) | AU726704B2 (et) |
| BG (1) | BG62985B1 (et) |
| BR (1) | BR9611901A (et) |
| CA (1) | CA2239709A1 (et) |
| CO (1) | CO4520233A1 (et) |
| CZ (1) | CZ174198A3 (et) |
| DE (1) | DE59610248D1 (et) |
| DK (1) | DK0865609T3 (et) |
| EE (1) | EE03783B1 (et) |
| ES (1) | ES2190484T3 (et) |
| HK (1) | HK1011560A1 (et) |
| MX (1) | MX9804459A (et) |
| NO (1) | NO319903B1 (et) |
| NZ (1) | NZ324314A (et) |
| PL (1) | PL184521B1 (et) |
| PT (1) | PT865609E (et) |
| SK (1) | SK284378B6 (et) |
| TR (1) | TR199801027T2 (et) |
| UY (1) | UY24389A1 (et) |
| WO (1) | WO1997021104A1 (et) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20030103985A1 (en) | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
| EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| CZ20033476A3 (cs) * | 2001-05-18 | 2004-05-12 | Boehringeráingelheimáinternationalágmbh | Protilátky specifické pro CD@@v |
| US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
| EP1391213A1 (en) * | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP1417974A1 (en) * | 2002-11-08 | 2004-05-12 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy |
| RU2599447C2 (ru) * | 2010-02-04 | 2016-10-10 | Юниверсити Оф Майами | Моноклональные антетела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи |
| US9218450B2 (en) * | 2012-11-29 | 2015-12-22 | Roche Molecular Systems, Inc. | Accurate and fast mapping of reads to genome |
| KR20210004961A (ko) * | 2018-02-22 | 2021-01-13 | 아브마트 상하이 컴퍼니, 엘티디. | 치료 항체 및 그의 용도 |
| WO2023227644A2 (en) | 2022-05-25 | 2023-11-30 | Akiram Therapeutics Ab | Binding protein |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69406664T2 (de) * | 1993-06-18 | 1998-06-04 | Biotie Therapies Oy | Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6 |
| EP0705436A1 (de) * | 1993-06-22 | 1996-04-10 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verfahren zur diagnose und analyse von mammakarzinomen |
| DE4326573A1 (de) * | 1993-08-07 | 1995-02-23 | Boehringer Ingelheim Int | Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren |
| UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
-
1996
- 1996-12-03 UY UY24389A patent/UY24389A1/es not_active IP Right Cessation
- 1996-12-04 AR ARP960105480A patent/AR004360A1/es unknown
- 1996-12-05 JP JP9520993A patent/JP2000502067A/ja not_active Ceased
- 1996-12-05 CZ CZ981741A patent/CZ174198A3/cs unknown
- 1996-12-05 SK SK736-98A patent/SK284378B6/sk unknown
- 1996-12-05 ES ES96942362T patent/ES2190484T3/es not_active Expired - Lifetime
- 1996-12-05 DE DE59610248T patent/DE59610248D1/de not_active Expired - Fee Related
- 1996-12-05 TR TR1998/01027T patent/TR199801027T2/xx unknown
- 1996-12-05 NZ NZ324314A patent/NZ324314A/en unknown
- 1996-12-05 AU AU11773/97A patent/AU726704B2/en not_active Ceased
- 1996-12-05 PL PL96327066A patent/PL184521B1/pl not_active IP Right Cessation
- 1996-12-05 CN CNB961992484A patent/CN1151377C/zh not_active Expired - Fee Related
- 1996-12-05 DK DK96942362T patent/DK0865609T3/da active
- 1996-12-05 EP EP96942362A patent/EP0865609B1/de not_active Expired - Lifetime
- 1996-12-05 CA CA002239709A patent/CA2239709A1/en not_active Abandoned
- 1996-12-05 AT AT96942362T patent/ATE235056T1/de not_active IP Right Cessation
- 1996-12-05 EE EE9800164A patent/EE03783B1/et not_active IP Right Cessation
- 1996-12-05 CO CO96063967A patent/CO4520233A1/es unknown
- 1996-12-05 WO PCT/EP1996/005448 patent/WO1997021104A1/de not_active Application Discontinuation
- 1996-12-05 BR BR9611901A patent/BR9611901A/pt not_active Application Discontinuation
- 1996-12-05 KR KR10-1998-0704242A patent/KR100473824B1/ko not_active IP Right Cessation
- 1996-12-05 PT PT96942362T patent/PT865609E/pt unknown
-
1998
- 1998-06-04 MX MX9804459A patent/MX9804459A/es not_active IP Right Cessation
- 1998-06-05 BG BG102513A patent/BG62985B1/bg unknown
- 1998-06-05 NO NO19982588A patent/NO319903B1/no unknown
- 1998-12-07 HK HK98112910A patent/HK1011560A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT865609E (pt) | 2003-08-29 |
| NO982588L (no) | 1998-08-05 |
| EE9800164A (et) | 1998-12-15 |
| DK0865609T3 (da) | 2003-06-23 |
| AU1177397A (en) | 1997-06-27 |
| TR199801027T2 (xx) | 1998-10-21 |
| ES2190484T3 (es) | 2003-08-01 |
| SK284378B6 (sk) | 2005-02-04 |
| KR19990071952A (ko) | 1999-09-27 |
| DE59610248D1 (de) | 2003-04-24 |
| EE03783B1 (et) | 2002-06-17 |
| EP0865609A1 (de) | 1998-09-23 |
| PL184521B1 (pl) | 2002-11-29 |
| BG102513A (en) | 1999-02-26 |
| WO1997021104A1 (de) | 1997-06-12 |
| CN1207811A (zh) | 1999-02-10 |
| NO982588D0 (no) | 1998-06-05 |
| BR9611901A (pt) | 1999-03-02 |
| CN1151377C (zh) | 2004-05-26 |
| JP2000502067A (ja) | 2000-02-22 |
| CO4520233A1 (es) | 1997-10-15 |
| SK73698A3 (en) | 1999-01-11 |
| HK1011560A1 (en) | 1999-07-16 |
| PL327066A1 (en) | 1998-11-23 |
| MX9804459A (es) | 1998-09-30 |
| AR004360A1 (es) | 1998-11-04 |
| NZ324314A (en) | 2000-02-28 |
| UY24389A1 (es) | 2001-10-25 |
| KR100473824B1 (ko) | 2005-09-30 |
| BG62985B1 (bg) | 2000-12-29 |
| EP0865609B1 (de) | 2003-03-19 |
| CZ174198A3 (cs) | 1999-02-17 |
| ATE235056T1 (de) | 2003-04-15 |
| CA2239709A1 (en) | 1997-06-12 |
| AU726704B2 (en) | 2000-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5916561A (en) | Monoclonal antibody against CD44v6 | |
| KR102308812B1 (ko) | 암 진단에 유용한 클라우딘 18.2에 대한 항체 | |
| NO319903B1 (no) | Anvendelse av et antistoffmolekyl for fremstilling av et farmasoytisk preparat for behandling av plateepitelkarsinom. | |
| US20130039931A1 (en) | Antibodies Against A Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof | |
| AU2013370171B2 (en) | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer | |
| US6372441B1 (en) | Method for diagnosis and therapy of Hodgkin's lymphomas | |
| CA2168988A1 (en) | Polypeptides coded by exon v5 of the cd44 gene as targets for immunotherapy and immunoscintigraphy of tumours | |
| MXPA96006108A (es) | Anticuerpos monoclonales contra cd44v6 | |
| Tang et al. | Evaluation of human major histocompatibility complex class I chain-related A as a potential target for tumor imaging | |
| RU2193779C2 (ru) | Средство и способ лечения плоскоклеточного рака | |
| MXPA99005544A (es) | Molecula de anticuerpo y su empleo para la diagnosis y terapia de linfomas de hodgkin |